|1.||Kim, Young-Joo: 2 articles (01/2014 - 10/2011)|
|2.||Yang, Hyun Ok: 2 articles (01/2014 - 10/2011)|
|3.||Kwon, Hak Cheol: 2 articles (01/2014 - 10/2011)|
|4.||Park, Hyun Bong: 2 articles (01/2014 - 10/2011)|
|5.||Yoo, Ji-Hye: 1 article (01/2014)|
|6.||Kim, Joonki: 1 article (01/2014)|
|7.||Park, Jin-Soo: 1 article (10/2011)|
|8.||Lee, Kang Ro: 1 article (10/2011)|
|2.||Prostatic Neoplasms (Prostate Cancer)
01/01/2014 - "Taken together, these findings provide a detailed description of the mechanism underlying the biological activity of the new natural product glionitrin A, which has the potential to be developed as an anti-prostate cancer agent. "
01/01/2014 - "Here, we investigated the antitumor activity of glionitrin A and its underlying molecular mechanisms in human prostate cancer DU145 cells. "
10/28/2011 - "In contrast to glionitrin A (2), glionitrin B (1) is not cytotoxic against the human prostate cancer cell line DU145. "
|3.||Ataxia Telangiectasia (Louis Bar Syndrome)
01/01/2014 - "Glionitrin A-treated cells exhibited elevated levels of phospho-histone 2AX (Ser139), a marker of DNA damage, and accumulated in both S phase and G2/M phase due to the activation of checkpoints associated with the ataxia-telangiectasia-mutated and ataxia-telangiectasia-mutated-Rad3-related Chk1/2 pathway downstream of p53-binding protein 1 phosphorylation at Ser1778. "
|1.||Heterologous Transplantation (Xenotransplantation)